학술논문

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
Document Type
Article
Source
BMJ: British Medical Journal; 2/13/2021, Vol. 372 Issue 8279, p1-9, 9p
Subject
ARTIFICIAL respiration
BIOMARKERS
C-reactive protein
CONFIDENCE intervals
FERRITIN
LACTATE dehydrogenase
OXYGEN therapy
SERUM
RANDOMIZED controlled trials
TREATMENT effectiveness
SEVERITY of illness index
FIBRIN fibrinogen degradation products
DESCRIPTIVE statistics
ODDS ratio
TOCILIZUMAB
COVID-19
PHARMACODYNAMICS
Language
ISSN
17561833